JCM
VRTX icon

Janney Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Janney Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$7.05M Sell
15,542
-165
-1% -$71.1K 0.44% 87
2025
Q3 		$6.15M Sell
15,707
-524
-3% -$219K 0.38% 91
2025
Q2 		$7.23M Sell
16,231
-276
-2% -$127K 0.47% 88
2025
Q1 		$8M Sell
16,507
-82
-0.5% -$38.2K 0.55% 84
2024
Q4 		$6.68M Sell
16,589
-566
-3% -$262K 0.44% 86
2024
Q3 		$7.98M Sell
17,155
-183
-1% -$87.9K 0.54% 83
2024
Q2 		$8.13M Sell
17,338
-69
-0.4% -$29.9K 0.57% 72
2024
Q1 		$7.28M Sell
17,407
-491
-3% -$208K 0.48% 85
2023
Q4 		$7.28M Sell
17,898
-192
-1% -$70.9K 0.49% 82
2023
Q3 		$6.29M Sell
18,090
-113
-0.6% -$39.5K 0.48% 75
2023
Q2 		$6.41M Sell
18,203
-216
-1% -$72.8K 0.44% 82
2023
Q1 		$5.8M Buy
18,419
+598
+3% +$179K 0.44% 80
2022
Q4 		$5.15M Buy
+17,821
New +$5.43M 0.37% 89

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janney Capital Management's VRTX Position: Q4 2025 in Review

Janney Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q4 2025, selling an estimated $71.1K and leaving 15,542 shares worth $7.05M. The position accounts for 0.44% of the portfolio, ranked #87.

Janney Capital Management first reported a position in VRTX in Q4 2022 and has held it in 13 quarters since. The position peaked at $8.13M in Q2 2024. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Janney Capital Management held 15,542 shares of Vertex Pharmaceuticals worth $7.05M as of Q4 2025.
  • Janney Capital Management sold 165 Vertex Pharmaceuticals shares in Q4 2025, an estimated $71.1K.
  • Vertex Pharmaceuticals made up 0.44% of Janney Capital Management's portfolio in Q4 2025, its #87 holding.
  • Janney Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • Janney Capital Management's Vertex Pharmaceuticals position peaked at $8.13M in Q2 2024.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Janney Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.